Compare AVNS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVNS | IMMP |
|---|---|---|
| Founded | 2014 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.7M | 410.7M |
| IPO Year | 2014 | 2012 |
| Metric | AVNS | IMMP |
|---|---|---|
| Price | $12.97 | $2.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 519.4K | 161.2K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.59 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $701,200,000.00 | N/A |
| Revenue This Year | $3.28 | $382.75 |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.95 | N/A |
| 52 Week Low | $9.30 | $1.32 |
| 52 Week High | $15.68 | $3.53 |
| Indicator | AVNS | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 37.90 | 49.22 |
| Support Level | $12.75 | $2.74 |
| Resistance Level | $13.18 | $3.24 |
| Average True Range (ATR) | 0.58 | 0.13 |
| MACD | -0.27 | -0.01 |
| Stochastic Oscillator | 6.48 | 53.22 |
Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.